Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

What is SmartPluse Technology and what are the benefits?

Poster Details

First Author: M. Arbelaez OMAN

Co Author(s):    S. Arba Mosquera                    

Abstract Details


To evaluate the clinical outcomes of SmartSurfACE compared to previous TransPRK in a retrospective setting.


Muscat Eye laser Center, Muscat ,Oman


The outcomes of SmartSurfACE have been evaluated up to 12M follow-up in 100 eyes and compared to a historic cohort of 100 previous TransPRK treatments. In all cases standard examinations, pre- and postoperative corneal-wavefront analyses (OPTIKON Scout), and ocular-wavefront aberrometries (Ocular Wavefront Analyzer) were performed. CAM software was used to plan Aberration-Free treatments and AMARIS system was used to perform ablations (SCHWIND eye-tech-solutions). Optimised astigmatic corrections were evaluated in terms of efficacy, predictability, stability, safety, and aberrations outcomes.


SmartSurfACE shows improved UDVA outcomes compared to previous TransPRK from Day 1 (3 lines better) to 1 month (1 line better) postoperatively (p<0.05). At 1 week postoperatively, 42% of the SmartSurfACE treatments reach 20/20 or better, vs. only 16% of the previous TransPRK. Results become equivalent at 3 months (p>0.05) with 100% of the patients having UDVA of 20/25 or better.


The short term superiority in the SmartSurfACE group could be attributed to the improved residual roughness (enhanced smoothness) of the corneal surface.

Financial Disclosure:

One or more of the authors is employed by a forNONEprofit company with an interest in the subject of the presentation, One or more of the authors travel has been funded, fully or partially, by a competing company

Back to Poster listing